Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma

NCT05228808 | Unknown

• 1 other identifier: Soh-Med-22-01-30
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Pancreatic carcinoma is ranked the 11th most common cancer worldwide. It is a highly lethal malignant tumor. In Egypt, the disease has traditionally been considered rare, but population in the East Nile Delta region exhibits an unusually high rate of young-onset pancreatic carcinoma. Pancreatic ductal adenocarcinoma is by far the most common histologic subtype of pancreatic malignancy. Programmed death ligand-1 (PD-L1) is a type I trans-membrane glycoprotein. It has an important prognostic and predictive value in various neoplasms. To date, few studies have addressed the potential prognostic role of PD-L1 in pancreatic carcinoma, so knowledge about its prognostic value needs further elucidation.

Conditions

Pancreatic Adenocarcinoma

Keywords

Pancreatic ductal adenocarcinoma; PD-L1; Prognostic value

Outcome Measures

Primary Outcomes (2)

• evaluate the expression of PD-L1 in pancreatic ductal adenocarcinoma

  Immunohistochemical study

  1 month

• correlate PD-L1 expression to different studied histopathological parameters to evaluate its prognostic value.

  Statistical analysis

  1 month

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Fifty specimens of pancreatic adenocarcinoma obtained from patients who underwent surgery, according to local Ethical Committee regulations, to be examined in the Pathology Laboratory of Sohag Faculty of Medicine. From January 2022 till completing the sample size.

You may qualify if:

• Patients with pancreatic ductal adenocarcinoma who underwent surgery.

You may not qualify if:

• Patients received pre-operative chemotherapy or radiotherapy.
• Patients with insufficient clinical data.
• Specimens with extensive necrosis
• Tiny specimens which are insufficient for accurate diagnosis.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Faculty of Medicine, Sohag University

Sohag, Egypt

RECRUITING

Study Officials

• Nagwa Ahmed, Lecturer

  Sohag University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nagwa Ahmed, Lecturer

CONTACT

01017415996; nagwa.sadek@med.sohag.edu.eg

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer at Pathology Department, Faculty of Medicine, Sohag University

Study Record Dates

• First Submitted: January 27, 2022
• First Posted: February 8, 2022
• Study Start: February 1, 2022
• Primary Completion: June 1, 2022
• Study Completion: December 1, 2022
• Last Updated: February 8, 2022

Record last verified: 2022-01

Locations

EG (1)